June 01, 2011 08:52 ET

Equity Research on Elan Corp. plc and Valeant Pharmaceuticals International - M&A in Drug Delivery Sector

NEW YORK, NY--(Marketwire - Jun 1, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Delivery industry and are offering free analytical research on Elan Corp. plc (NYSE: ELN) and Valeant Pharmaceuticals International (NYSE: VRX). Register with us today at to have free access to this research or speak to one of our pros at

Mergers and acquisitions are quite common in the Drug Delivery sector. Companies often sell portions of their businesses to pay off debts or fund research and development. When patent cliffs loom, it is also quite common for companies to look to acquisitions to ensure they have a strong line up of products to sell. Get instant analyses of Elan Corp. plc and Valeant Pharmaceuticals International from live, real-time experts standing by at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Elan Corp. plc and Valeant Pharmaceuticals International then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Elan Corp. plc, for example, sold its drug technology unit called EDT for $960 million this month. The company said it will use a portion of the cash from the sale to fund research and development. Elan Corp. plc report is accessible for free by registering today at

Elsewhere in the sector, after reporting strong results in its first quarter on the back of surging revenue, Valeant Pharmaceuticals International has said this month that it will acquire the pharmaceutical company AB Sanitas for 314 million Euros in an effort to expand its offerings in Eastern Europe. Like most of the sector, the company has been aggressively pursuing acquisitions to boost its growth. Valeant Pharmaceuticals International report is accessible for free by registering today at

The two Drug Delivery stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information